In order to evaluate the impact of the immunotherapies on the immune tumor microenvironment, we analyzed, by flow cytometry, the T cell population into the tumor, focusing on regulatory and CD8+ cytotoxic T cells among the CD45+ cells. The gene discussed is PTPRC; the disease is neoplasm.